David P. Goldstein
University Health Network, University of Toronto, Princess Margaret Cancer Centre
Papers
18
Total Citations
1,118
H-Index
12
About
David P. Goldstein is a prominent head and neck surgical oncologist whose research has fundamentally shaped the treatment landscape for oropharyngeal squamous cell carcinoma (OPSCC). His work centers on transoral robotic surgery (TORS), comparative treatment effectiveness, and surgical innovation in head and neck oncology. Goldstein is perhaps best known for leading the landmark ORATOR trial — a pioneering randomized phase 2 study comparing radiotherapy to TORS with neck dissection for oropharyngeal cancer — which has accumulated nearly 460 citations since 2019 and provided some of the first high-quality evidence directly comparing these two treatment modalities. His systematic reviews evaluating TORS against intensity-modulated radiotherapy, cited over 250 times, helped establish early evidence frameworks guiding clinical decision-making. Goldstein has also made important contributions to cost-effectiveness analysis, demonstrating the economic viability of TORS, and to the surgical workup of head and neck cancers of unknown primary origin. His innovative pilot work integrating intraoperative image guidance into robotic surgery reflects a commitment to advancing surgical precision. Collectively, his research — spanning clinical trials, systematic reviews, health economics, and emerging technologies — has profoundly influenced how clinicians approach the diagnosis and treatment of oropharyngeal malignancies worldwide.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10Intraoperative image guidance in transoral robotic surgery: A pilot study13 citations · 2017